Search

Your search keyword '"Ferreira, João Pedro"' showing total 1,608 results
Start Over Author "Ferreira, João Pedro"
1,608 results on '"Ferreira, João Pedro"'

1. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

Author

Wei, Fang-Fei, Pellicori, Pierpaolo, Ferreira, João Pedro, González, Arantxa, Mariottoni, Beatrice, An, De-Wei, Verdonschot, Job A. J., Liu, Chen, Ahmed, Fozia Z., Petutschnigg, Johannes, Rossignol, Patrick, Heymans, Stephane, Cuthbert, Joe, Girerd, Nicolas, Clark, Andrew L., Li, Yan, Nawrot, Tim S., Díez, Javier, Zannad, Faiez, Cleland, John G. F., and Staessen, Jan A.

Published
2024
Full Text
View/download PDF

6. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF

Author

Shen, Li, Dewan, Pooja, Ferreira, João Pedro, Cunningham, Jonathan W., Jhund, Pardeep S., Anand, Inder S., Chandra, Alvin, Chiang, Lu-May, Claggett, Brian, Desai, Akshay S., Gong, Jianjian, Lam, Carolyn S. P., Lefkowitz, Martin P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Redfield, Margaret M., Rouleau, Jean L., van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., Solomon, Scott D., and McMurray, John J. V.

Published
2024
Full Text
View/download PDF

7. A INTELIGENCIA ARTIFICIAL

Author

Ferreira, João Pedro Sampel, primary, Mancinelli, Amanda Cristina, additional, Lourenco, Luis Fernando, additional, and Rodrigues, João Pedro, additional

Published
2024
Full Text
View/download PDF

8. FARMACOLOGIA DOS ANALGÉSICOS: PERSPECTIVAS ATUAIS E FUTURAS

Author

Ferreira, João Pedro Gomes, primary, Souza, Gustavo Teixeira de, additional, Amaral, Kauanny Ribeiro Do, additional, Jorge, Vinicius Castro Figueiredo, additional, Bastos Filho, Fábio Lucas Pinheiro, additional, Philocreon, Rodrigo de Deus Costa, additional, Cardoso, João Victor Santana da Rocha, additional, and Santos, Lucas Eduardo Duarte, additional

Published
2024
Full Text
View/download PDF

9. DOR NEUROPÁTICA EM PACIENTES IDOSOS: AVALIAÇÃO E TRATAMENTO

Author

Filho, José Nicolas Andraos, primary, de Andrade, Carlos Augusto Pícoli, additional, Ferreira, João Pedro Gomes, additional, Taveira, Arthur Borges, additional, Charafeddine, Cassem Saboya, additional, Goulart, Letho Carrilho, additional, Tomasini, Isadora Correia Gomes, additional, Camilo, Kaic Toledo, additional, de Souza, Gustavo Teixeira, additional, and Carneiro, Antônio Fernando, additional

Published
2024
Full Text
View/download PDF

25. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Author

Anker, Stefan D., Butler, Javed, Usman, Muhammad Shariq, Filippatos, Gerasimos, Ferreira, João Pedro, Bocchi, Edimar, Böhm, Michael, Rocca, Hans Pieter Brunner-La, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L., González-Juanatey, José R., Merkely, Bela, Nicholls, Stephen J., Perrone, Sergio V., Piña, Ileana L., Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Iwata, Tomoko, Schnee, Janet M., Brueckmann, Martina, Pocock, Stuart J., and Zannad, Faiez

Published
2022
Full Text
View/download PDF

28. Hypokalemia is frequent and has prognostic implications in stable patients attending the emergency department

Author

Vuillaume, Laure Abensur, Ferreira, João Pedro, Asseray, Nathalie, Trombert-Paviot, Béatrice, Montassier, Emmanuel, Legrand, Matthieu, Girerd, Nicolas, Boivin, Jean-Marc, Chouihed, Tahar, and Rossignol, Patrick

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Services, Clinical Research, Aged, Cross-Sectional Studies, Emergency Medical Services, Emergency Service, Hospital, Female, Hospitalization, Humans, Hypokalemia, Male, Middle Aged, Prognosis, Prospective Studies, Treatment Outcome, General Science & Technology
Abstract

BackgroundPotassium disturbances are associated with adverse prognosis in patients with chronic conditions. Its prognostic implications in stable patients attending the emergency department (ED) is poorly described.AimsThis study aimed to assess the prevalence of dyskalemia, describe its predisposing factors and prognostic associations in a population presenting the ED without unstable medical illness.MethodsPost-hoc analysis of a prospective, cross-sectional, multicenter study in the ED of 11 French academic hospitals over a period of 8 weeks. All adults presenting to the ED during this period were included, except instances of self-drug poisoning, inability to complete self-medication questionnaire, presence of an unstable medical illness and decline to participate in the study. All-cause hospitalization or deaths were assessed.ResultsA total of 1242 patients were included. The mean age was 57.2±22.3 years, 51% were female. The distribution according to potassium concentrations was: hypokalemia5mmol/L(n = 73, 0,6%). The proportion of patients with a kalemia

Published
2020

29. Hypokalemia is frequent and has prognostic implications in stable patients attending the emergency department.

Author

Abensur Vuillaume, Laure, Ferreira, João Pedro, Asseray, Nathalie, Trombert-Paviot, Béatrice, Montassier, Emmanuel, Legrand, Matthieu, Girerd, Nicolas, Boivin, Jean-Marc, Chouihed, Tahar, and Rossignol, Patrick

Subjects
Humans, Hypokalemia, Prognosis, Treatment Outcome, Hospitalization, Prospective Studies, Cross-Sectional Studies, Aged, Middle Aged, Emergency Service, Hospital, Emergency Medical Services, Female, Male, General Science & Technology
Abstract

BackgroundPotassium disturbances are associated with adverse prognosis in patients with chronic conditions. Its prognostic implications in stable patients attending the emergency department (ED) is poorly described.AimsThis study aimed to assess the prevalence of dyskalemia, describe its predisposing factors and prognostic associations in a population presenting the ED without unstable medical illness.MethodsPost-hoc analysis of a prospective, cross-sectional, multicenter study in the ED of 11 French academic hospitals over a period of 8 weeks. All adults presenting to the ED during this period were included, except instances of self-drug poisoning, inability to complete self-medication questionnaire, presence of an unstable medical illness and decline to participate in the study. All-cause hospitalization or deaths were assessed.ResultsA total of 1242 patients were included. The mean age was 57.2±22.3 years, 51% were female. The distribution according to potassium concentrations was: hypokalemia5mmol/L(n = 73, 0,6%). The proportion of patients with a kalemia

Published
2020

38. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Garibaldi, Brian T., Albertson, Timothy E., Sandrock, Christian, Lee, Janet S., Looney, Mark R., Tapson, Victor F., Wiysonge, Charles Shey, Velarde, Luis Humberto Anaya, Backenroth, Daniel, Bhushanan, Jisha, Brandenburg, Börries, Cárdenas, Vicky, Chen, Bohang, Chen, Fei, Chetty, Polan, Chu, Pei-Ling, Cooper, Kimberly, Custers, Jerome, Delanghe, Hilde, Duca, Anna, Henrick, Tracy, Juraszek, Jarek, Nalpas, Catherine, Peeters, Monika, Pinheiro, Jose, Roels, Sanne, Ryser, Martin F., Salas, Jose, Santoro Matias, Samantha, Scheys, Ilse, Shetty, Pallavi, Shukarev, Georgi, Stoddard, Jeffrey, Talloen, Willem, Tran, NamPhuong, Vaissiere, Nathalie, van Son-Palmen, Elisabeth, Xu, Jiajun, Goecker, Erin A., Greninger, Alexander L., Jerome, Keith R., Roychoudhury, Pavitra, Takuva, Simbarashe G., Accini Mendoza, Jose Luis, Achtyes, Eric, Ahsan, Habibul, Alhatemi, Azhar, Allen, Nancy, Arribas, Jose R., Bahrami, Ghazaleh, Bailon, Lucia, Bajwa, Ali, Baker, Jonathan, Baron, Mira, Benet, Susana, Berdaï, Driss, Berger, Patrick, Bertoch, Todd, Bethune, Claire, Bevilacqua, Sybille, Biagioni Santos, Maria Silvia, Binnian, Ian, Bisnauthsing, Karen, Boivin, Jean-Marc, Bollen, Hilde, Bonnet, Sandrine, Borobia, Alberto M., Botelho-Nevers, Elisabeth, Bright, Phil, Britten, Vianne, Brown, Claire, Buadi, Amanda, Buntinx, Erik, Burgess, Lesley, Bush, Larry, Capeding, Maria Rosario, Carr, Quito Osuna, Carrasco Mas, Amparo, Catala, Hélène, Cathie, Katrina, Caudill, T. Shawn, Cereto Castro, Fernando, Chau, Kénora, Chavoustie, Steven, Chowdhury, Marie, Chronos, Nicolas, Cicconi, Paola, Cifuentes, Liliana, Cobo, Sara Maria, Collins, Helen, Colton, Hayley, Cuaño, Carlos Rolando G., D'Onofrio, Valentino, Dargan, Paul, Darton, Thomas, Deane, Peter, Del Pozo, Jose Luis, Derdelinckx, Inge, Desai, Amisha, Dever, Michael, Díaz-Pollán, Beatriz, DiBuono, Mark, Doust, Matthew, Duncan, Christopher, Echave-Sustaeta, Jose Maria, Eder, Frank, Ellis, Kimberly, Elzi, Stanton, Emmett, Stevan, Engelbrecht, Johannes, Evans, Mim, Farah, Theo, Felton, Timothy, Ferreira, João Pedro, Floutier, Catherine, Flume, Patrick, Ford, Stacy, Fragoso, Veronica, Freedman, Andrew, Frentiu, Emilia, Galloway, Christopher, Galtier, Florence, Garcia Diaz, Julia, García García, Irene, Garcia, Alcaide, Gardener, Zoe, Gauteul, Pascale, Geller, Steven, Gibson, Andrew, Gillet, Claudia, Girerd, Nicolas, Girodet, Pierre-Olivier, Gler, Maria Tarcela, Glover, Richard, Go, Herschel Don D., Gokani, Karishma, Gonthier, Damien, Green, Christopher, Greenberg, Richard, Griffin, Carl, Grobbelaar, Coert, Guancia, Adonis, Hakkarainen, Gloria, Harris, James, Hassman, Michael, Heimer, Deirdre, Hellstrom-Louw, Elizabeth, Herades, Yoan, Holroyd, Christopher, Hussen, Nazreen, Isidro, Marie Grace Dawn, Jackson, Yvonne, Jain, Manish, João Filho, Esaú Custódio, Johnson, Daniel, Jones, Ben, Joseph, Natasha, Jumeras, Analyn, Junquera, Patricia, Kellett-Wright, Johanna, Kennedy, Patrick, Kilgore, Paul E., Kim, Kenneth, Kimmel, Murray, Konis, George, Kutner, Mark, Lacombe, Karine, Launay, Odile, Lazarus, Rajeka, Lederman, Samuel, Lefebvre, Gigi, Lennon Collins, Katrina, Leroux-Roels, Isabel, Lim, Kenneth Wilson O., Lins, Muriel, Liu, Edward, Llewelyn, Martin, Mahomed, Akbar, Maia, Bernardo Porto, Marín-Candon, Alícia, Martínez-Gómez, Xavier, Martinot, Jean Benoit, Mazzella, Andrea, McCaughan, Frank, McCormack, Louise, McGettigan, John, Mehra, Purvi, Mejeur, Rhonda, Miller, Vicki, Mills, Anthony, Molto Marhuenda, Jose, Moodley, Prebashan, Mora-Rillo, Marta, Mothe, Beatriz, Mullan, Daniel, Munro, Alasdair, Myers, Paul, Nell, Jeremy, Newman Lobato Souza, Tamara, O'Halloran, Jane A., Ochoa Mazarro, Maria Dolores, Oliver, Abigail, Onate Gutierrez, Jose Millan, Ortega, Jessica, Oshita, Masaru, Otero Romero, Susana, Overcash, Jeffrey Scott, Owens, Daniel, Packham, Alice, Pacurar, Mihaela, Paiva de Sousa, Leonardo, Palfreeman, Adrian, Pallares, Christian José, Patel, Rahul, Patel, Suchet, Pelkey, Leslie, Peluso, Denise, Penciu, Florentina, Pinto, S. Jerry, Pounds, Kevin, Pouzar, Joe, Pragalos, Antoinette, Presti, Rachel, Price, David, Qureshi, Ehsaan, Ramalho Madruga, José Valdez, Ramesh, Mayur, Rankin, Bruce, Razat, Béatrice, Riegel Santos, Breno, Riesenberg, Robert, Riffer, Ernie, Roche, Siobhan, Rose, Katie, Rosellini, Pietro, Rossignol, Patrick, Safirstein, Beth, Salazar, Hernan, Sanchez Vallejo, Gregorio, Santhosh, Smrithi, Seco-Meseguer, Enrique, Seep, Michael, Sherry, Emma, Short, Philip, Soentjens, Patrick, Solis, Joel, Soriano Viladomiu, Alejandro, Sorli, Caroline, Spangenthal, Selwyn, Spence, Niamh, Stephenson, Elaine, Strout, Cynthia, Surowitz, Ronald, Taladua, Kristy Michelle, Tellalian, David, Thalamas, Claire, Thiriphoo, Nang, Thomas, Judith, Thomas, Nicholas, Trout, Guillermo, Urroz, Mikel, Veekmans, Bernard, Veekmans, Laurent, Villalobos, Ralph Elvi M., Warren, Sarah, Webster, Brian, White, Alexander, Williams, Gail, Williams, Hayes, Wilson, Barbara, Winston, Alan, Wiselka, Martin, Zervos, Marcus, Hardt, Karin, Vandebosch, An, Sadoff, Jerald, Le Gars, Mathieu, Truyers, Carla, Lowson, David, Van Dromme, Ilse, Vingerhoets, Johan, Kamphuis, Tobias, Scheper, Gert, Ruiz-Guiñazú, Javier, Faust, Saul N, Spinner, Christoph D, Schuitemaker, Hanneke, Van Hoof, Johan, Douoguih, Macaya, and Struyf, Frank

Published
2022
Full Text
View/download PDF

39. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Author

Mehra, Mandeep R, Vaduganathan, Muthiah, Fu, Min, Ferreira, João Pedro, Anker, Stefan D, Cleland, John GF, Lam, Carolyn SP, van Veldhuisen, Dirk J, Byra, William M, Spiro, Theodore E, Deng, Hsiaowei, Zannad, Faiez, and Greenberg, Barry

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Research, Brain Disorders, Neurosciences, Stroke, Clinical Trials and Supportive Activities, Heart Disease, Cardiovascular, Heart Disease - Coronary Heart Disease, Patient Safety, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Brain Ischemia, Case-Control Studies, Coronary Artery Disease, Double-Blind Method, Drug Therapy, Combination, Factor Xa Inhibitors, Female, Heart Failure, Hemorrhage, Humans, Incidence, Ischemic Attack, Transient, Male, Middle Aged, Myocardial Infarction, Placebos, Platelet Aggregation Inhibitors, Rivaroxaban, Stroke Volume, Heart failure, Oral anticoagulation, Thrombotic, Transient ischaemic attack, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

AimsStroke is often a devastating event among patients with heart failure with reduced ejection (HFrEF). In COMMANDER HF, rivaroxaban 2.5 mg b.i.d. did not reduce the composite of first occurrence of death, stroke, or myocardial infarction compared with placebo in patients with HFrEF, coronary artery disease (CAD), and sinus rhythm. We now examine the incidence, timing, type, severity, and predictors of stroke or a transient ischaemic attack (TIA), and seek to establish the net clinical benefit of treatment with low-dose rivaroxaban.Methods and resultsIn this double-blind, randomized trial, 5022 patients who had HFrEF(≤40%), elevated natriuretic peptides, CAD, and who were in sinus rhythm were treated with rivaroxaban 2.5 mg b.i.d. or placebo in addition to antiplatelet therapy, after an episode of worsening HF. The primary neurological outcome for this post hoc analysis was time to first event of any stroke or TIA. Over a median follow-up of 20.5 (25th-75th percentiles 20.0-20.9) months, 150 all-cause stroke (127) or TIA (23) events occurred (ischaemic stroke in 82% and haemorrhagic stroke in 11% of stroke events). Overall, 47.5% of first-time strokes were either disabling (16.5%) or fatal (31%). Prior stroke, low body mass index, geographic region, and the CHA2DS2-VASc score were predictors of stroke/TIA. Rivaroxaban significantly reduced the primary neurological endpoint of all-cause stroke or TIA compared with placebo by 32% (1.29 events vs. 1.90 events per 100 patient-years), adjusted for the time from index HF event to randomization and stratified by geographic region (adjusted hazard ratio 0.68, 95% confidence interval 0.49-0.94), with a number needed to treat of 164 patients per year to prevent one stroke/TIA event. The principal safety endpoint of fatal bleeding or bleeding into a critical space, occurred at a similar rate on rivaroxaban and placebo (0.44 events vs. 0.55 events per 100 patient-years).ConclusionsPatients with HFrEF and CAD are at risk for stroke or TIA in the period following an episode of worsening heart failure in the absence of atrial fibrillation. Most strokes are of ischaemic origin and nearly half are either disabling or fatal. Rivaroxaban at a dose of 2.5 mg b.i.d. reduced rates of stroke or TIA compared with placebo in this population.Trial registrationCOMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure); ClinicalTrials.gov NCT01877915.

Published
2019

47. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Author

Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, and Ponikowski, Piotr

Published
2022
Full Text
View/download PDF

50. A broad-band study of the evolving emission-line properties of galaxies

Author

Ferreira, João Pedro de Jesus, Dunlop, James, and McLure, Ross

Subjects
523.1, high-redshift, galaxies, photometry, colour, star formation, emission lines
Abstract

This thesis describes a new approach to the study of high-redshift star-formation and its environments that can be applied to large high-redshift surveys. Instead of relying on spectroscopy or narrow-band photometry to study galaxy line emission in detail, the properties of large emission line galaxy (ELG)populations are estimated from broadband photometry by measuring colour-residuals against colours drawn from a set of line-free stochastic burst models-based on (Bruzual & Charlot, 2003). Simulated star-formation histories drawn from semi-analytic and adaptive-mesh-refinement codes were converted into mock galaxy colours, but neither could-span the range of observed galaxy colours at high redshift. Instead, an existing set of exponentially declining star-formation models with stochastic bursts was used, because it closely spanned the range in observed galaxy colours in the bandsthat were line-free at each redshift. Small colour offsets were measured between the models and the observations, corresponding to the equivalent widths (EWs)of Hα, [OIII] and [OII]. In this way, I measure the rest-frame Equivalent Widths of the Hα, [OIII]and [OII] emission lines as they are redshifted through all filters from CANDELS(near-continuous U to 4.5μm coverage) for a large sample of galaxies from z=0.1up to z=5. This approach relies solely on the line-free models, a set of existing reliable photometric redshifts, and a colour cut (B−K < 2 or equivalent) to select only the dust-free young objects (the majority of identified emission-line galaxies). Once correctly identified, I apply this method to the CANDELS-UDS photometry to characterise the properties of Emission-Line Galaxies (ELGs) through these lines. I find that in this sample the Hα and [OIII] ELG fraction with EW > 150Årises from < 5% at z < 1 up to 40% at z > 2. The co-moving ELG density rises from 5 to 30 ×10 −4 /Mpc −3 at z=2.3. The evolution of median Hα EW with redshift is consistent with results from HiZELS and 3D-HST yielding median EW ∼ M 0.25 (1+z) 1.75 up to z=2.3, from which it departs to values of 450Å atz=4.3. [OIII] remains weaker than Hα for z < 3 and matches its values above that redshift. [OIII] also displays a larger fraction of extreme EWs than Hα. [OII], while correctly identified, never becomes as extreme as the other two lines lines, even when corrected for the evolving continuum. This is evidence of an increasing [OIII]/[OII] ratio with increasing z through-out this sample. While these results agree with spectroscopic and narrow-band surveys, the use of the deeper broadband filter coverage enables a systematic measurement of the increasingly prevalent high EWs ( > 500Å) in galaxies at every redshift spanning the 10 8 to 10 10.5 M range. Subsequently, this method was applied to all the other CANDELS fields (GOODS-South and North, COSMOS and EGS) and further corroborates these results. These results further show that EW dependence on mass is steeper for [OIII] than for Hα. Line EWs are then converted into luminosities for the three lines and fitting formulas are obtained, displaying L Hα ∼(1+z) 3.2 M 0.45−0.6log(1+z), with similar results for the other lines. L Hα is converted into star-formation rate and specific star-formation rate (sSFR). sSFR at low-z aligns approximately with the main sequence (with a steeper dependence in mass), but at high-redshift sSFR remains above the main sequence by a factor of 2 and rising towards medians SFR=100/Gyr around log(M/M )=9, showing a departure of the main sequence of star formation at lower masses log(M/M ) < 9.5. The SFRD of ELGs is 1% at low redshift, but rises to 30% at z=4.5. The L [OIII] /L Hα ratio is used to estimate L [OIII] /L Hβ and the ionization parameter q, for which the median atz > 0.5 stays approximately constant at 10 8 cm/s, and increases with mass. Using the L [OIII] /L [OII] ratio and q, median metallicity is shown to be sub-solar, and can be tentatively estimated for z > 0.5 to be Z/Z ∼0.3. The errors are large, but this could also mean a large range in metallicity from Z to 0.1Z . L [OIII] /L [OII] rises with sSFR as shown in the literature. This method shows great potential to survey emission-line-derived physical quantities for large galaxy populations with a low computational footprint, which could be particularly useful for pixel-by-pixel EW imaging. It is also flexibile, which allows it to be applied to any future deep multi-broadband fields.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results